Skip to main content

CSL share price lifts on HY23 results | CSL Limited (ASX:CSL)

Sophia Mavridis
February 14, 2023

Biotherapeutics company, CSL Limited (ASX:CSL), reported its half year earnings today, beating forecasts, and the market has responded positively.

For the six months, CSL reported a 19% increase in revenue to US$7,183 million, as well as a 10% lift in net profit after tax before amortisation in constant currency to US$1,957 million. Citi were expecting NPAT of US$1,795 million.

CSL’s earnings were partly driven by a five-month contribution from Vifor Pharma, as well as impressive sales growth and record levels of plasma collections.

CSL have lifted its interim dividend by 2.9% to US$1.07 per share.

And management reaffirmed its guidance for FY2023 NPAT in the range of US$2.7 billion to US$2.8 billion at constant currency.

CSL’s share price has been on the rise today, currently trading 0.6% higher at AU$306.88, at the time of recording.

Morning Bell 24 March

Jessica Amir
March 24, 2021

Morning Bell 23 March

Jessica Amir
March 23, 2021

Morning Bell 22 March

Jessica Amir
March 22, 2021

Weekly Wrap 19 March

Jessica Amir
March 19, 2021

Morning Bell 19 March

Jessica Amir
March 19, 2021

Morning Bell 18 March

Jessica Amir
March 18, 2021

Morning Bell 17 March

Jessica Amir
March 17, 2021

Morning Bell 16 March

Jessica Amir
March 16, 2021

Morning Bell 15 March

Jessica Amir
March 15, 2021

Weekly Wrap 12 March

Jessica Amir
March 12, 2021

Morning Bell 12 March

Jessica Amir
March 12, 2021

Morning Bell 11 March

Bell Direct
March 11, 2021